Bard Financial Services Inc. Has $2.47 Million Position in Kenvue Inc. (NYSE:KVUE)

Bard Financial Services Inc. lifted its position in shares of Kenvue Inc. (NYSE:KVUE) by 5.7% in the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 106,790 shares of the company’s stock after buying an additional 5,750 shares during the period. Bard Financial Services Inc.’s holdings in Kenvue were worth $2,470,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds also recently modified their holdings of the company. Soltis Investment Advisors LLC boosted its position in shares of Kenvue by 3.7% during the third quarter. Soltis Investment Advisors LLC now owns 151,858 shares of the company’s stock worth $3,512,000 after buying an additional 5,475 shares during the period. TD Private Client Wealth LLC boosted its position in shares of Kenvue by 5.6% during the third quarter. TD Private Client Wealth LLC now owns 129,127 shares of the company’s stock worth $2,987,000 after buying an additional 6,901 shares during the period. Sunbelt Securities Inc. boosted its position in Kenvue by 3.1% during the third quarter. Sunbelt Securities Inc. now owns 29,671 shares of the company’s stock valued at $686,000 after purchasing an additional 905 shares during the last quarter. Financial Avengers Inc. boosted its position in Kenvue by 15.6% during the third quarter. Financial Avengers Inc. now owns 46,530 shares of the company’s stock valued at $1,076,000 after purchasing an additional 6,278 shares during the last quarter. Finally, Coldstream Capital Management Inc. boosted its position in Kenvue by 2.6% during the third quarter. Coldstream Capital Management Inc. now owns 26,017 shares of the company’s stock valued at $602,000 after purchasing an additional 653 shares during the last quarter. 97.64% of the stock is owned by institutional investors and hedge funds.

Kenvue Price Performance

Shares of NYSE KVUE opened at $22.90 on Wednesday. The firm has a market cap of $43.91 billion, a P/E ratio of 41.35, a price-to-earnings-growth ratio of 2.07 and a beta of 1.37. The company has a current ratio of 1.00, a quick ratio of 0.69 and a debt-to-equity ratio of 0.66. Kenvue Inc. has a 1-year low of $17.67 and a 1-year high of $24.46. The business’s 50 day moving average is $22.96 and its 200-day moving average is $21.15.

Kenvue (NYSE:KVUE) last announced its quarterly earnings data on Thursday, November 7th. The company reported $0.28 earnings per share for the quarter, beating the consensus estimate of $0.27 by $0.01. The firm had revenue of $3.90 billion during the quarter, compared to analysts’ expectations of $3.92 billion. Kenvue had a return on equity of 21.43% and a net margin of 6.88%. The company’s quarterly revenue was down .4% compared to the same quarter last year. During the same period in the previous year, the firm earned $0.31 EPS. Equities research analysts predict that Kenvue Inc. will post 1.07 earnings per share for the current year.

Kenvue Dividend Announcement

The business also recently disclosed a quarterly dividend, which was paid on Wednesday, November 27th. Shareholders of record on Wednesday, November 13th were issued a $0.205 dividend. The ex-dividend date was Wednesday, November 13th. This represents a $0.82 annualized dividend and a yield of 3.58%. Kenvue’s dividend payout ratio is presently 149.09%.

Wall Street Analyst Weigh In

Several research analysts recently commented on KVUE shares. Royal Bank of Canada raised Kenvue from a “hold” rating to a “moderate buy” rating in a research report on Monday. Jefferies Financial Group started coverage on Kenvue in a research report on Tuesday, September 24th. They set a “buy” rating and a $27.00 price target for the company. Bank of America increased their price target on Kenvue from $24.00 to $27.00 and gave the company a “buy” rating in a research report on Tuesday, October 22nd. JPMorgan Chase & Co. increased their price target on Kenvue from $24.00 to $25.00 and gave the company an “overweight” rating in a research report on Friday, October 11th. Finally, Piper Sandler increased their price target on Kenvue from $20.00 to $21.00 and gave the company a “neutral” rating in a research report on Monday, September 23rd. One investment analyst has rated the stock with a sell rating, six have assigned a hold rating and four have assigned a buy rating to the stock. Based on data from MarketBeat, the company presently has a consensus rating of “Hold” and a consensus price target of $22.64.

Kenvue Profile

Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.